September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to this noninvasive diagnostic imaging tool may pose a greater risk to patients than rare side effects associated with use, according to doctors who spoke today at the 37th International 

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of 

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of death in Korea, is a deadly disease with an initial mortality rate of 30%, and about 5-10% of patients die even if they are transported to a medical center for treatment.

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart & Vascular Institute, has now shown through a clinical study to significantly decrease cardiovascular mortality, reduce additional non-invasive heart testing, and increase cath lab efficiency.

September 13, 2023 — Socioeconomic status (education, income, employment status and health insurance) appears to be an uneven predictor of heart health with white adults benefitting the most in comparison to Black, Hispanic and Asian Americans, according to a study led by researchers at 

September 13, 2023 — The Smidt Heart Institute at Cedars-Sinai has earned a prestigious designation for its excellence in adult and pediatric extracorporeal membrane oxygenation, or ECMO--an often lifesaving treatment where blood is pumped outside of a patient’s body to a portable heart-lung machine, giving the patient’s own organs a re

September 13, 2023 — Blood pressure among patients diagnosed with hypertension appeared to slightly increase, and rates of systolic, or top number, blood pressure being controlled during an outpatient visit appeared to slightly decrease during winter months, according to a new study presented during the American Heart Association (AHA) Hypertens

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now